News

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss the long-term efficacy of sonelokimab, with more than 60% of patients achieving HiSCR75 and approximately 30% reaching HiSCR100.

Phase 3 data presented at AAD 2026 show once-daily oral therapy clears skin as early as week 4, offering a fast-acting option for patients.

This portion of the AMETHYST trial is the second successful phase 2 study of litifilimab, an investigational monoclonal antibody for CLE.

Late-breaking data shared at AAD 2026 supports oral TYK2 envudeucitinib's efficacy and safety in moderate-to-severe plaque psoriasis.

At AAD 2026, Christopher Bunick, MD, PhD, and Patrick Burnett, MD, PhD, discuss late-breaking data of roflumilast cream's improvements in infants with AD.

Pelage’s PP405 novel topical reawakens dormant follicle stem cells, showing signs of terminal regrowth and fueling late-stage alopecia research.

Late-breaking phase 2 findings presented at AAD show nemolizumab achieved high EASI-90 rates and rapid itch relief in pediatric patients with atopic dermatitis.

Panelists discuss the role of communication, follow-up, and safety monitoring in optimizing long-term biologic therapy outcomes.

Catch up on coverage from the first day of the 2026 American Academy of Dermatology Annual Meeting held in Denver, Colorado.

Nicole Negbenebor, MD, highlights the clinical and professional impact of community-driven education and evidence-based focus in skin of color dermatology.

Christopher Bunick, MD, PhD, interviews medical student Sabine Obagi on the value of conference participation, mentorship, and early exposure for aspiring dermatology clinicians at AAD 2026.

Melanoma cases keep rising, but AI-aided screening, gene profiling, and newer immunotherapies boost early diagnosis and long-term survival, according to Darrell Rigel, MD, MS.

This year’s AAD poster awards highlight studies advancing skin cancer prevention, inflammatory disease management, and complex dermatology care.

BE HEARD extension data underscore the importance of early diagnosis and treatment initiation to optimize long-term outcomes in hidradenitis suppurativa.

With 80% of trial participants being children, this analysis provides some of the most robust early-response data available for a non-steroidal topical in pediatric AD.

Read more on how to navigate all the opportunities at this year’s AAD meeting, which starts today in Denver, Colorado.

The GLODERM Pre–AAD meeting emphasized that global skin health progress now depends on translating policy into scalable, equitable care delivery.

At the pre-AAD meeting, Regina Benjamin, MD, MBA, discussed the role of clinicians as leaders in addressing social determinants of health, emphasizing prevention, education, and culturally responsive care.

In a patient with longstanding Hailey-Hailey disease, lebrikizumab was associated with rapid improvement in symptoms and quality of life.

These leaders are shaping the future of dermatology through their clinical expertise, research, and educational presentations.

Levy reflected on the importance of mentorship, collaboration, and the evolving landscape of pediatric dermatology at the Society for Pediatric Dermatology Pre-AAD Meeting.

Despite declining skin care sales post-pandemic, fragrance products remain strong, prompting increased investment from cosmetic companies.

The rise of at-home injectable trends is exposing patients to risks including infection, nerve damage, and potential systemic complications.

Guardrails and disclaimers are essential for responsible AI deployment in dermatology, according to Faranak Kamangar, MD.

Who is a woman who has shaped your life and career in dermatology? Hear stories from our experts as we celebrate Women's History Month 2026.

Targeted therapies are increasingly used earlier in treatment rather than being reserved for severe or refractory cases.

This review of the latest dermatological studies includes insights on vitiligo cultural beliefs, home-based phototherapy, digital search behavior in NSV patients, and more.

Misconceptions about vitiligo, including contagion and supernatural causation, remain prevalent in many regions and are linked to increased stigma.

Linda Stein Gold, MD, FAAD, shares her thoughts on FDA-approved, once-daily oral icotrokinra for teens and adults with moderate to severe plaque psoriasis, promising biologic-like results, strong safety, and earlier systemic escalation.